March 7, 2025 - 07:20

Sophie Smith, the founder of Nabta Health, a pioneering hybrid healthcare company focused on women's health in the Gulf Cooperation Council (GCC), recently shared her insights on the region's health-tech sector. In a conversation with Paul Allen on the Horizons Middle East and Africa show, Smith discussed the significance of Nabta Health's recent Series A funding round. This investment not only bolsters the company's operations but also emphasizes its commitment to advancing research and development within the healthcare space.
Smith highlighted the growing potential of the Gulf's health-tech scene, noting a surge in interest and investment that is reshaping the landscape. As the only women-focused hybrid healthcare provider in the region, Nabta Health is uniquely positioned to address the specific health needs of women, which have often been overlooked. The future looks promising for health-tech innovations in the Gulf, as companies like Nabta Health lead the way in delivering tailored healthcare solutions.
April 19, 2026 - 00:02
IMG Academy, Neuro Challenge Foundation host Parkinson’s wellness event focused on movement and brain healthA unique event at IMG Academy is helping people with Parkinson’s disease stay active while raising awareness about the importance of movement and community support. The recent wellness gathering...
April 18, 2026 - 04:30
\'It\'s personal to me\': Bill requiring mental health awareness training for coaches passes in state HouseA bill requiring mental health awareness training for school athletics staff is headed to the Pennsylvania Senate after passing in the state House on Wednesday. The proposed legislation, which...
April 17, 2026 - 03:07
New Leadership Nominated for the Centers for Disease Control and PreventionIn a move to stabilize a key public health agency, Erica Schwartz has been nominated to serve as the next director of the Centers for Disease Control and Prevention. The nomination comes at a...
April 16, 2026 - 02:18
RFK Jr. promotes peptides. Now the FDA weighs easing limits on the unproven chemicalsThe U.S. Food and Drug Administration is moving to re-evaluate its stance on a group of unapproved chemicals known as peptides, following a surge in public interest and promotion by high-profile...